Evidence map›Paper›PMID 38180344›Full record

ArticleImmunoHorizons2024

TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity.

Kishore R Alugupalli

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Tiny but mighty: small molecules as vaccine adjuvants.Trends in pharmacological sciences · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Kishore R AlugupalliORCID 0000-0001-8092-514X
Thomas Jefferson University · US

Funding

Stem cell origins of human fetal/neonatal B cell subsetsR21AI151737 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ALUGUPALLI, KISHORE R, MANSER, TIMOTHY L · 2020 to 2021
$429k
A System to Study Salmonella Typhi Infection and ImmunityR21AI159798 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ALUGUPALLI, KISHORE R · 2021 to 2022
$429k
NIAID NIH HHS R21 AI151737NIAID NIH HHS R21 AI159798
6 · The paper itself

Abstract

Activation of B cells and T cells requires the engagement of costimulatory signaling pathways in addition to Ag receptor signaling for efficient immune responses. None of the typhoid Vi polysaccharide (ViPS) subunit vaccines contains adjuvants that could activate costimulatory signaling pathways, yet these vaccines are very immunogenic. I hypothesized that residual TLR ligands present in the ViPS preparation used for making typhoid subunit vaccines account for the robust immune response generated by these vaccines. I show the presence of endotoxin, a potent agonist of TLR4, in ViPS preparations and ViPS vaccines. Furthermore, I found that ViPS obtained from various sources induces the production of proinflammatory cytokines such as IL-6 from mouse peritoneal exudate cells. Unconjugated and tetanus toxoid-conjugated ViPS vaccines activate human and mouse TLR4. Mice deficient in TLR4 or the signaling adaptors MyD88 and Trif (Toll/IL-1R domain-containing adapter inducing IFN-β) are severely impaired in generating anti-ViPS responses to these vaccines. Elimination of the TLR4 agonist in ViPS preparation resulted in the loss of immunogenicity, and addition of lipid A, a known TLR4 agonist, restored the immunogenicity. These data highlight the importance of associated TLR ligands in the immunogenicity of ViPS subunit vaccines.

Indexed as

Immunogenicity, VaccineToll-Like Receptor 4Typhoid FeverTyphoid-Paratyphoid VaccinesAdaptor Proteins, Signal TransducingAdjuvants, ImmunologicAnimalsB-LymphocytesHumansLigandsMiceVaccines, SubunitAdaptor Proteins, Signal TransducingAdjuvants, ImmunologicLigandsTLR4 protein, humanToll-Like Receptor 4Typhoid-Paratyphoid VaccinesVaccines, Subunit

Identifiers

PMID38180344
PMCPMC10832388
OpenAlexW4390631580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.